GlassScriptPhysician profile
Kerby Barker
NPI 1629953260
$1,070.64
in general payments reported to CMS, 2019-2025
17 companies · $1,071 in 2025
The $1,071 reported for 2025 was more than what 88% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $993 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $992.65 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $373.04 | 2025 | Talvey, Darzalex, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $114.40 | 2025 | Enhertu, Tagrisso |
| Novartis Pharmaceuticals Corporation | $81.98 | 2025 | |
| Daiichi Sankyo INC. | $62.98 | 2025 | Enhertu, Datroway |
| Tersera Therapeutics LLC | $54.79 | 2025 | Xermelo, Zoladex |
| Abbvie INC. | $51.90 | 2025 | |
| Genentech USA, INC. | $46.65 | 2025 | Itovebi, Tecentriq |
| Glaxosmithkline, LLC. | $42.41 | 2025 | Ojjaara, Zejula, Jemperli |
| Aveo Pharmaceuticals, INC. | $39.96 | 2025 | |
| Springworks Therapeutics, INC. | $34.02 | 2025 | Ogsiveo |
| Genzyme Corporation | $31.93 | 2025 | |
| Recordati_rare_diseases_inc. | $29.94 | 2025 | Enjaymo |
| Takeda Pharmaceuticals U.S.A., INC. | $25.36 | 2025 | Iclusig |
| Pharmaessentia USA Corporation | $24.61 | 2025 | Besremi |
| Janssen Pharmaceuticals, INC | $22.62 | 2025 | Darzalex, Talvey, Tecvayli |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $17.08 | 2025 | |
| Astellas Pharma US INC | $16.97 | 2025 | Xtandi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerby Barker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.